{"id":338040,"date":"2025-08-19T13:36:34","date_gmt":"2025-08-19T13:36:34","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-crispr-therapeutics-ag\/"},"modified":"2025-08-19T13:36:34","modified_gmt":"2025-08-19T13:36:34","slug":"how-to-buy-crispr-therapeutics-ag","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-338040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) v\u1edbi ph\u00e2n t\u00edch gi\u00e1 hi\u1ec7n t\u1ea1i, d\u1ef1 b\u00e1o n\u0103m 2025 v\u00e0 c\u00e1c chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0 t\u1eebng b\u01b0\u1edbc cho c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) v\u1edbi ph\u00e2n t\u00edch gi\u00e1 hi\u1ec7n t\u1ea1i, d\u1ef1 b\u00e1o n\u0103m 2025 v\u00e0 c\u00e1c chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0 t\u1eebng b\u01b0\u1edbc cho c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen."},"intro":"Ch\u1ec9nh s\u1eeda gen \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng \u0111\u1ed9t ph\u00e1 y h\u1ecdc c\u00e1ch m\u1ea1ng nh\u1ea5t c\u1ee7a th\u1ebf h\u1ec7 ch\u00fang ta, v\u00e0 CRISPR Therapeutics \u0111\u1ee9ng \u1edf tuy\u1ebfn \u0111\u1ea7u c\u1ee7a s\u1ef1 chuy\u1ec3n \u0111\u1ed5i n\u00e0y. \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRSP c\u00f3 ngh\u0129a l\u00e0 b\u1ea1n \u0111ang mua v\u00e0o c\u00f4ng ngh\u1ec7 c\u00f3 th\u1ec3 \u0111\u1ecbnh ngh\u0129a l\u1ea1i c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh di truy\u1ec1n m\u00e3i m\u00e3i. C\u00f4ng ty ti\u00ean phong trong c\u00f4ng ngh\u1ec7 CRISPR\/Cas9 mang l\u1ea1i ti\u1ec1m n\u0103ng ch\u01b0a t\u1eebng c\u00f3 cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi \u0111\u1ed5i m\u1edbi c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ti\u00ean ti\u1ebfn.","intro_source":{"label":"Intro","type":"text","formatted_value":"Ch\u1ec9nh s\u1eeda gen \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng \u0111\u1ed9t ph\u00e1 y h\u1ecdc c\u00e1ch m\u1ea1ng nh\u1ea5t c\u1ee7a th\u1ebf h\u1ec7 ch\u00fang ta, v\u00e0 CRISPR Therapeutics \u0111\u1ee9ng \u1edf tuy\u1ebfn \u0111\u1ea7u c\u1ee7a s\u1ef1 chuy\u1ec3n \u0111\u1ed5i n\u00e0y. \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRSP c\u00f3 ngh\u0129a l\u00e0 b\u1ea1n \u0111ang mua v\u00e0o c\u00f4ng ngh\u1ec7 c\u00f3 th\u1ec3 \u0111\u1ecbnh ngh\u0129a l\u1ea1i c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh di truy\u1ec1n m\u00e3i m\u00e3i. C\u00f4ng ty ti\u00ean phong trong c\u00f4ng ngh\u1ec7 CRISPR\/Cas9 mang l\u1ea1i ti\u1ec1m n\u0103ng ch\u01b0a t\u1eebng c\u00f3 cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi \u0111\u1ed5i m\u1edbi c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ti\u00ean ti\u1ebfn."},"body_html":"<h2>M\u1edf Kh\u00f3a T\u01b0\u01a1ng Lai Y H\u1ecdc Qua \u0110\u1ea7u T\u01b0 C\u1ed5 Phi\u1ebfu<\/h2> <p>Ch\u1ec9nh s\u1eeda gen \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng \u0111\u1ed9t ph\u00e1 y h\u1ecdc c\u00e1ch m\u1ea1ng nh\u1ea5t c\u1ee7a th\u1ebf h\u1ec7 ch\u00fang ta, v\u00e0 CRISPR Therapeutics \u0111\u1ee9ng \u1edf tuy\u1ebfn \u0111\u1ea7u c\u1ee7a s\u1ef1 chuy\u1ec3n \u0111\u1ed5i n\u00e0y. \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRSP c\u00f3 ngh\u0129a l\u00e0 b\u1ea1n \u0111ang mua v\u00e0o c\u00f4ng ngh\u1ec7 c\u00f3 th\u1ec3 \u0111\u1ecbnh ngh\u0129a l\u1ea1i c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh di truy\u1ec1n m\u00e3i m\u00e3i. C\u00f4ng ty ti\u00ean phong trong c\u00f4ng ngh\u1ec7 CRISPR\/Cas9 mang l\u1ea1i ti\u1ec1m n\u0103ng ch\u01b0a t\u1eebng c\u00f3 cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi \u0111\u1ed5i m\u1edbi c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ti\u00ean ti\u1ebfn.<\/p> <p><strong>\u1ea2nh Ch\u1ee5p Gi\u00e1 C\u1ed5 Phi\u1ebfu Hi\u1ec7n T\u1ea1i<\/strong><\/p> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 19 th\u00e1ng 8 n\u0103m 2025, CRISPR Therapeutics AG (CRSP) giao d\u1ecbch \u1edf m\u1ee9c <strong>57,59 USD<\/strong> m\u1ed7i c\u1ed5 phi\u1ebfu. C\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n s\u1ef1 bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong su\u1ed1t n\u0103m 2025, ph\u1ea3n \u00e1nh c\u1ea3 ti\u1ec1m n\u0103ng to l\u1edbn v\u00e0 r\u1ee7i ro \u0111\u00e1ng k\u1ec3 v\u1ed1n c\u00f3 trong \u0111\u1ea7u t\u01b0 ch\u1ec9nh s\u1eeda gen. V\u1edbi ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 30,04 USD \u0111\u1ebfn 71,13 USD, CRSP cung c\u1ea5p ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3 c\u00f9ng v\u1edbi r\u1ee7i ro gi\u1ea3m gi\u00e1 kh\u00f4ng nh\u1ecf.<\/p> <p><strong>C\u1ea3nh B\u00e1o Ng\u00e0y Quan Tr\u1ecdng: 4 Th\u00e1ng 11, 2025<\/strong><\/p> <p>H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y 4 th\u00e1ng 11 n\u0103m 2025 \u2013 \u0111\u00e2y l\u00e0 ng\u00e0y CRISPR Therapeutics s\u1ebd c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 n\u0103m 2025. C\u00e1c m\u1eabu h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o thu nh\u1eadp n\u00e0y th\u01b0\u1eddng k\u00edch ho\u1ea1t c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3. B\u00e1o c\u00e1o qu\u00fd 2 g\u1ea7n \u0111\u00e2y c\u1ee7a c\u00f4ng ty v\u00e0o ng\u00e0y 4 th\u00e1ng 8 n\u0103m 2025 cung c\u1ea5p c\u00e1i nh\u00ecn s\u00e2u s\u1eafc v\u1ec1 nh\u1eefng g\u00ec c\u00f3 th\u1ec3 mong \u0111\u1ee3i.<\/p> <p>Trong b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 2 n\u0103m 2025, CRISPR \u0111\u00e3 v\u01b0\u1ee3t qua \u01b0\u1edbc t\u00ednh EPS (-1,29 USD so v\u1edbi -1,47 USD d\u1ef1 ki\u1ebfn) nh\u01b0ng l\u1ea1i b\u1ecf l\u1ee1 d\u1ef1 b\u00e1o doanh thu \u0111\u00e1ng k\u1ec3 (0,89 tri\u1ec7u USD so v\u1edbi 6,44 tri\u1ec7u USD d\u1ef1 ki\u1ebfn). M\u00f4 h\u00ecnh hi\u1ec7u su\u1ea5t h\u1ed7n h\u1ee3p n\u00e0y \u0111\u00e3 \u0111\u01b0\u1ee3c duy tr\u00ec:<\/p> <ul> <li><strong>Th\u00e1ng 2 n\u0103m 2025<\/strong>: V\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh EPS v\u1edbi b\u1ea5t ng\u1edd doanh thu m\u1ea1nh<\/li> <li><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: B\u1ecf l\u1ee1 c\u1ea3 m\u1ee5c ti\u00eau EPS v\u00e0 doanh thu<\/li> <li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: V\u01b0\u1ee3t EPS nh\u01b0ng b\u1ecf l\u1ee1 doanh thu m\u1ed9t c\u00e1ch \u0111\u00e1ng k\u1ec3<\/li> <\/ul> <p>B\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11 s\u1ebd \u0111\u1eb7c bi\u1ec7t quan tr\u1ecdng khi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 theo d\u00f5i c\u1eadp nh\u1eadt v\u1ec1 ti\u1ebfn tr\u00ecnh th\u01b0\u01a1ng m\u1ea1i h\u00f3a CASGEVY v\u00e0 c\u00e1c ph\u00e1t tri\u1ec3n th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng cho c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh CTX310 v\u00e0 CTX112.<\/p> [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng: T\u00e0u L\u01b0\u1ee3n C\u1ea3m X\u00fac C\u1ee7a \u0110\u1ed5i M\u1edbi<\/h2> <p>CRISPR Therapeutics \u0111\u00e3 \u0111\u01b0a c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t chuy\u1ebfn \u0111i hoang d\u00e3 trong t\u00e1m th\u00e1ng \u0111\u1ea7u n\u0103m 2025, mang l\u1ea1i l\u1ee3i nhu\u1eadn <strong>51,75% t\u1eeb \u0111\u1ea7u n\u0103m \u0111\u1ebfn nay<\/strong> m\u1eb7c d\u00f9 c\u00f3 s\u1ef1 bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3.<\/p> <p><strong>D\u00f2ng Th\u1eddi Gian Bi\u1ebfn \u0110\u1ed9ng Gi\u00e1:<\/strong><\/p> <ul> <li><strong>Th\u00e1ng 1 n\u0103m 2025<\/strong>: Giao d\u1ecbch quanh m\u1ee9c 40-45 USD sau \u0111\u1ee3t gi\u1ea3m n\u0103m 2024<\/li> <li><strong>Th\u00e1ng 3 n\u0103m 2025<\/strong>: T\u0103ng d\u1ea7n l\u00ean 48-52 USD nh\u1edd l\u1ea1c quan v\u1ec1 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/li> <li><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: T\u0103ng v\u1ecdt l\u00ean 58-62 USD nh\u1edd tin t\u1ee9c v\u1ec1 c\u1ed9t m\u1ed1c quy \u0111\u1ecbnh<\/li> <li><strong>Th\u00e1ng 7 n\u0103m 2025<\/strong>: \u0110\u1ec9nh \u0111i\u1ec3m \u1edf 64,76 USD v\u1edbi th\u00f4ng b\u00e1o m\u1edf r\u1ed9ng CASGEVY<\/li> <li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: T\u00edch l\u0169y quanh 57-60 USD v\u1edbi ho\u1ea1t \u0111\u1ed9ng ch\u1ed1t l\u1eddi<\/li> <\/ul> <p>Hi\u1ec7u su\u1ea5t c\u1ee7a c\u1ed5 phi\u1ebfu th\u1ec3 hi\u1ec7n \u0111\u1eb7c \u0111i\u1ec3m \u0111i\u1ec3n h\u00ecnh c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u2013 t\u0103ng m\u1ea1nh khi c\u00f3 tin t\u00edch c\u1ef1c v\u00e0 sau \u0111\u00f3 l\u00e0 giai \u0111o\u1ea1n t\u00edch l\u0169y. M\u1ee9c <strong>t\u0103ng 35-40% t\u1eeb th\u00e1ng 6 \u0111\u1ebfn th\u00e1ng 7<\/strong> cho th\u1ea5y t\u00e2m l\u00fd c\u00f3 th\u1ec3 thay \u0111\u1ed5i nhanh ch\u00f3ng trong l\u0129nh v\u1ef1c n\u00e0y d\u1ef1a tr\u00ean c\u1eadp nh\u1eadt l\u00e2m s\u00e0ng v\u00e0 ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh.<\/p> <h2>D\u1ef1 B\u00e1o Gi\u00e1: \u0110\u1ecbnh H\u01b0\u1edbng Bi\u00ean Gi\u1edbi \u0110\u1ea7u T\u01b0 Di Truy\u1ec1n<\/h2> <ul> <li><strong>M\u1ee5c Ti\u00eau Cu\u1ed1i N\u0103m 2025: 86-91 USD<\/strong><br>C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n CRSP c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 86,42 \u0111\u1ebfn 91,28 USD v\u00e0o th\u00e1ng 12 n\u0103m 2025, t\u01b0\u01a1ng \u0111\u01b0\u01a1ng m\u1ee9c t\u0103ng ti\u1ec1m n\u0103ng 50-58% so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i. S\u1ef1 l\u1ea1c quan n\u00e0y xu\u1ea5t ph\u00e1t t\u1eeb k\u1ef3 v\u1ecdng t\u0103ng t\u1ed1c doanh thu CASGEVY v\u00e0 c\u00e1c k\u1ebft qu\u1ea3 d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c.<\/li> <li><strong>Tri\u1ec3n V\u1ecdng 2026: 83-85 USD<\/strong><br>T\u0103ng tr\u01b0\u1edfng v\u1eeba ph\u1ea3i h\u01a1n khi c\u00f4ng ty chuy\u1ec3n t\u1eeb giai \u0111o\u1ea1n nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n thu\u1ea7n t\u00fay sang giai \u0111o\u1ea1n th\u1ef1c thi th\u01b0\u01a1ng m\u1ea1i.<\/li> <li><strong>D\u1ef1 B\u00e1o 2028: 100-120 USD<\/strong><br>Gi\u1ea3 \u0111\u1ecbnh ph\u00e1t tri\u1ec3n th\u00e0nh c\u00f4ng pipeline v\u00e0 ph\u00ea duy\u1ec7t th\u00eam li\u1ec7u ph\u00e1p.<\/li> <li><strong>T\u1ea7m Nh\u00ecn 2030: 140-160 USD<\/strong><br>Ti\u1ec1m n\u0103ng d\u00e0i h\u1ea1n n\u1ebfu ch\u1ec9nh s\u1eeda gen tr\u1edf th\u00e0nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb y h\u1ecdc ph\u1ed5 bi\u1ebfn.<\/li> <li><strong>K\u1ebft Lu\u1eadn: MUA<\/strong> d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 ch\u1ecbu r\u1ee7i ro v\u1edbi t\u1ea7m nh\u00ecn d\u00e0i h\u1ea1n. Ti\u1ec1m n\u0103ng n\u1ec1n t\u1ea3ng c\u00f4ng ngh\u1ec7 c\u1ee7a c\u00f4ng ty v\u01b0\u1ee3t tr\u1ed9i so v\u1edbi c\u00e1c th\u00e1ch th\u1ee9c t\u00e0i ch\u00ednh ng\u1eafn h\u1ea1n.<\/li> <\/ul> <h2>\u0110\u00e1nh Gi\u00e1 R\u1ee7i Ro: \u0110i\u1ec1u H\u01b0\u1edbng M\u1ecf M\u00ecn C\u00f4ng Ngh\u1ec7 Sinh H\u1ecdc<\/h2> <ul> <li><strong>Nguy C\u01a1 Bi\u1ebfn \u0110\u1ed9ng Cao<\/strong><br>CRSP th\u1ec3 hi\u1ec7n dao \u0111\u1ed9ng gi\u00e1 c\u1ef1c \u0111oan v\u1edbi \u0111\u1ed9 bi\u1ebfn \u0111\u1ed9ng l\u1ecbch s\u1eed 30 ng\u00e0y l\u00e0 0,4585. C\u00e1c bi\u1ebfn \u0111\u1ed9ng h\u00e0ng ng\u00e0y t\u1eeb 4-8% l\u00e0 ph\u1ed5 bi\u1ebfn, khi\u1ebfn vi\u1ec7c x\u00e1c \u0111\u1ecbnh k\u00edch th\u01b0\u1edbc v\u1ecb th\u1ebf tr\u1edf n\u00ean quan tr\u1ecdng.<\/li> <li><strong>Lo Ng\u1ea1i V\u1ec1 T\u00ednh B\u1ec1n V\u1eefng T\u00e0i Ch\u00ednh<\/strong><br>C\u00f4ng ty ti\u00eau t\u1ed1n kho\u1ea3ng 200 tri\u1ec7u USD m\u1ed7i qu\u00fd trong khi doanh thu r\u1ea5t th\u1ea5p. T\u1ed1c \u0111\u1ed9 \u0111\u1ed1t ti\u1ec1n n\u00e0y \u0111\u00f2i h\u1ecfi huy \u0111\u1ed9ng v\u1ed1n trong t\u01b0\u01a1ng lai c\u00f3 th\u1ec3 l\u00e0m pha lo\u00e3ng c\u1ed5 \u0111\u00f4ng.<\/li> <li><strong>B\u1ea5t \u1ed4n Quy \u0110\u1ecbnh<\/strong><br>Ch\u1ec9nh s\u1eeda gen \u0111\u1ed1i m\u1eb7t v\u1edbi c\u00e1c khung ph\u00e1p l\u00fd \u0111ang ph\u00e1t tri\u1ec3n tr\u00ean to\u00e0n c\u1ea7u. B\u1ea5t k\u1ef3 quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c n\u00e0o v\u1ec1 quy \u0111\u1ecbnh c\u00f3 th\u1ec3 l\u00e0m gi\u00e1 c\u1ed5 phi\u1ebfu s\u1ee5p \u0111\u1ed5 qua \u0111\u00eam.<\/li> <li><strong>K\u1ebft Qu\u1ea3 Nh\u1ecb Ph\u00e2n Th\u1eed Nghi\u1ec7m L\u00e2m S\u00e0ng<\/strong><br>Th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m th\u01b0\u1eddng g\u00e2y gi\u1ea3m gi\u00e1 tr\u00ean 50%, trong khi th\u00e0nh c\u00f4ng c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t t\u0103ng gi\u00e1 tr\u00ean 100%.<\/li> <\/ul> <h2>T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c: Cu\u1ed9c C\u00e1ch M\u1ea1ng Di Truy\u1ec1n T\u0103ng T\u1ed1c<\/h2> <ul> <li><strong>M\u1edf R\u1ed9ng Th\u01b0\u01a1ng M\u1ea1i CASGEVY<\/strong><br>K\u00edch ho\u1ea1t 75 trung t\u00e2m \u0111i\u1ec1u tr\u1ecb \u0111\u01b0\u1ee3c \u1ee7y quy\u1ec1n tr\u00ean to\u00e0n c\u1ea7u \u0111\u1ea1i di\u1ec7n cho s\u1ef1 x\u00e2y d\u1ef1ng c\u01a1 s\u1edf h\u1ea1 t\u1ea7ng l\u1edbn, d\u1ef1 ki\u1ebfn th\u00fac \u0111\u1ea9y t\u0103ng tr\u01b0\u1edfng doanh thu trong giai \u0111o\u1ea1n 2025-2026.<\/li> <li><strong>T\u0103ng T\u1ed1c Ti\u1ebfn \u0110\u1ed9 Pipeline<\/strong><br>CTX310 \u0111\u01b0\u1ee3c FDA c\u00f4ng nh\u1eadn l\u00e0 li\u1ec7u ph\u00e1p ti\u00ean ti\u1ebfn trong y h\u1ecdc t\u00e1i t\u1ea1o v\u00e0 CTX112 m\u1edf r\u1ed9ng sang c\u00e1c b\u1ec7nh t\u1ef1 mi\u1ec5n t\u1ea1o ra nhi\u1ec1u ch\u1ea5t x\u00fac t\u00e1c gi\u00e1 tr\u1ecb.<\/li> <li><strong>\u0110\u1ed9ng L\u1ef1c Ng\u00e0nh<\/strong><br>Th\u1ecb tr\u01b0\u1eddng ch\u1ec9nh s\u1eeda gen d\u1ef1 ki\u1ebfn t\u0103ng tr\u01b0\u1edfng v\u1edbi t\u1ed1c \u0111\u1ed9 CAGR 22% \u0111\u1ebfn n\u0103m 2030, t\u1ea1o ra l\u00e0n s\u00f3ng thu\u1eadn l\u1ee3i cho t\u1ea5t c\u1ea3 c\u00e1c b\u00ean tham gia.<\/li> <li><strong>\u0110\u1ed1i T\u00e1c Chi\u1ebfn L\u01b0\u1ee3c<\/strong><br>H\u1ee3p t\u00e1c g\u1ea7n \u0111\u00e2y v\u1edbi Sirius Therapeutics ph\u00e1t tri\u1ec3n siRNA cho th\u1ea5y \u0111\u1ed9ng l\u1ef1c ph\u00e1t tri\u1ec3n kinh doanh.<\/li> <\/ul> <h2>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Tin T\u1ee9c G\u1ea7n \u0110\u00e2y<\/h2> <ul> <li><strong>B\u00e1o C\u00e1o Thu Nh\u1eadp Ng\u00e0y 4 Th\u00e1ng 8, 2025<\/strong>: Ph\u1ea3n \u1ee9ng h\u1ed7n h\u1ee3p v\u1edbi vi\u1ec7c v\u01b0\u1ee3t EPS nh\u01b0ng b\u1ecf l\u1ee1 doanh thu g\u00e2y nh\u1ea7m l\u1eabn ban \u0111\u1ea7u r\u1ed3i \u1ed5n \u0111\u1ecbnh.<\/li> <li><strong>Tri\u1ec3n Khai To\u00e0n C\u1ea7u CASGEVY<\/strong>: M\u1edf r\u1ed9ng trung t\u00e2m \u0111i\u1ec1u tr\u1ecb l\u00ean 75 \u0111\u1ecba \u0111i\u1ec3m t\u1ea1o \u0111\u1ed9ng l\u1ef1c t\u00edch c\u1ef1c b\u1ec1n v\u1eefng \u0111\u1ebfn th\u00e1ng 7.<\/li> <li><strong>M\u1edf R\u1ed9ng CTX112 Sang B\u1ec7nh T\u1ef1 Mi\u1ec5n<\/strong>: Th\u00f4ng b\u00e1o th\u00e1ng 7 k\u00edch ho\u1ea1t t\u0103ng gi\u00e1 16% trong m\u1ed9t ng\u00e0y khi nh\u00e0 \u0111\u1ea7u t\u01b0 nh\u1eadn ra l\u1ee3i \u00edch \u0111a d\u1ea1ng h\u00f3a pipeline.<\/li> <li><strong>\u0110\u01b0\u1ee3c TIME Vinh Danh<\/strong>: \u0110\u01b0\u1ee3c li\u1ec7t k\u00ea trong danh s\u00e1ch C\u00e1c C\u00f4ng Ty \u1ea2nh H\u01b0\u1edfng Nh\u1ea5t c\u1ee7a TIME mang l\u1ea1i uy t\u00edn v\u00e0 thu h\u00fat s\u1ef1 ch\u00fa \u00fd c\u1ee7a nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n.<\/li> <\/ul> <h2>K\u1ebft Lu\u1eadn Chi\u1ebfn L\u01b0\u1ee3c \u0110\u1ea7u T\u01b0<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u00e0 giao d\u1ecbch m\u1edbi b\u1eaft \u0111\u1ea7u h\u00f4m nay:<\/p> <ol> <li><strong>B\u1eaft \u0110\u1ea7u Nh\u1ecf<\/strong> \u2013 Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 2-3% danh m\u1ee5c cho CRSP do bi\u1ebfn \u0111\u1ed9ng c\u1ef1c \u0111oan<\/li> <li><strong>Trung B\u00ecnh Gi\u00e1 \u0110\u00f4 La<\/strong> \u2013 X\u00e2y d\u1ef1ng v\u1ecb th\u1ebf d\u1ea7n d\u1ea7n trong 3-6 th\u00e1ng thay v\u00ec \u0111\u1ea7u t\u01b0 m\u1ed9t l\u1ea7n l\u1edbn<\/li> <li><strong>\u0110\u1eb7t M\u1ee9c C\u1eaft L\u1ed7<\/strong> \u2013 B\u1ea3o v\u1ec7 kh\u1ecfi s\u1ee5t gi\u1ea3m th\u1ea3m kh\u1ed1c v\u1edbi m\u1ee9c c\u1eaft l\u1ed7 25-30%<\/li> <li><strong>Theo D\u00f5i B\u00e1o C\u00e1o Thu Nh\u1eadp Th\u00e1ng 11<\/strong> \u2013 Chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng l\u1edbn sau b\u00e1o c\u00e1o thu nh\u1eadp<\/li> <\/ol> <p>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc c\u1ee7a nh\u00e0 giao d\u1ecbch: \"Giao d\u1ecbch CRSP gi\u1ed1ng nh\u01b0 ch\u1ec9nh s\u1eeda gen \u2013 \u0111\u00f4i khi b\u1ea1n gh\u00e9p n\u1ed1i \u0111\u01b0\u1ee3c kho\u1ea3n \u0111\u1ea7u t\u01b0 ho\u00e0n h\u1ea3o, \u0111\u00f4i khi b\u1ea1n t\u1ea1o ra v\u1ecb th\u1ebf \u0111\u1ed9t bi\u1ebfn \u0103n m\u00f2n danh m\u1ee5c \u0111\u1ea7u t\u01b0 c\u1ee7a b\u1ea1n!\"<\/p> <h2>C\u00e1ch Mua C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP) - Th\u1ef1c Thi \u0110\u1ea7u T\u01b0<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea7m Quan Tr\u1ecdng Chi\u1ebfn L\u01b0\u1ee3c<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Nghi\u00ean C\u1ee9u C\u00e1c L\u1ef1a Ch\u1ecdn M\u00f4i Gi\u1edbi<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p truy c\u1eadp NASDAQ v\u00e0 c\u1ea5u tr\u00fac hoa h\u1ed3ng h\u1ee3p l\u00fd<\/td><\/tr> <tr><td>2<\/td><td>N\u1ea1p Ti\u1ec1n V\u00e0o T\u00e0i Kho\u1ea3n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf \u0111\u1ec3 th\u1eed chi\u1ebfn l\u01b0\u1ee3c tr\u01b0\u1edbc khi cam k\u1ebft l\u1edbn h\u01a1n<\/td><\/tr> <tr><td>3<\/td><td>L\u1ef1a Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td><td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o trong \u0111i\u1ec1u ki\u1ec7n bi\u1ebfn \u0111\u1ed9ng<\/td><\/tr> <tr><td>4<\/td><td>\u0110\u1ecbnh C\u1ee1 V\u1ecb Th\u1ebf<\/td><td>Gi\u1eef v\u1ecb th\u1ebf ban \u0111\u1ea7u d\u01b0\u1edbi 3% t\u1ed5ng gi\u00e1 tr\u1ecb danh m\u1ee5c<\/td><\/tr> <tr><td>5<\/td><td>Thi\u1ebft L\u1eadp Gi\u00e1m S\u00e1t<\/td><td>Thi\u1ebft l\u1eadp c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c ng\u00e0y b\u00e1o c\u00e1o thu nh\u1eadp v\u00e0 c\u00e1c m\u1ee9c k\u1ef9 thu\u1eadt<\/td><\/tr> <\/tbody> <\/table> <p>Qu\u00e1 tr\u00ecnh n\u00e0y \u0111\u00f2i h\u1ecfi hi\u1ec3u r\u1eb1ng \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc kh\u00e1c bi\u1ec7t c\u0103n b\u1ea3n so v\u1edbi ch\u1ecdn c\u1ed5 phi\u1ebfu truy\u1ec1n th\u1ed1ng. B\u1ea1n \u0111ang \u0111\u1eb7t c\u01b0\u1ee3c v\u00e0o th\u00e0nh c\u00f4ng khoa h\u1ecdc thay v\u00ec ch\u1ec9 l\u00e0 v\u01b0\u1ee3t k\u1ef3 v\u1ecdng thu nh\u1eadp qu\u00fd.<\/p> <h2>L\u1ee3i Th\u1ebf Pocket Option: C\u1eeda Ng\u00f5 \u0110\u1ebfn S\u1ef1 Gi\u00e0u C\u00f3 Di Truy\u1ec1n<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm l\u1ed1i v\u00e0o d\u1ec5 d\u00e0ng v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu ti\u1ec1m n\u0103ng cao nh\u01b0 CRSP, Pocket Option cung c\u1ea5p c\u00e1c l\u1ee3i th\u1ebf ri\u00eang bi\u1ec7t ph\u00f9 h\u1ee3p ho\u00e0n h\u1ea3o v\u1edbi chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc:<\/p> <ul> <li><strong>Y\u00eau C\u1ea7u N\u1ea1p Ti\u1ec1n T\u1ed1i Thi\u1ec3u Linh Ho\u1ea1t<\/strong><br>Ch\u1ec9 v\u1edbi y\u00eau c\u1ea7u n\u1ea1p t\u1ed1i thi\u1ec3u 5 USD, nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 th\u1eed nghi\u1ec7m v\u1edbi CRSP m\u00e0 kh\u00f4ng c\u1ea7n cam k\u1ebft v\u1ed1n l\u1edbn. \u0110i\u1ec1u n\u00e0y cho ph\u00e9p th\u1eed nghi\u1ec7m ki\u1ec3m so\u00e1t r\u1ee7i ro v\u1edbi c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng.<\/li> <li><strong>K\u00edch Ho\u1ea1t T\u00e0i Kho\u1ea3n Nhanh<\/strong><br>Quy tr\u00ecnh KYC m\u1ed9t t\u00e0i li\u1ec7u cho ph\u00e9p b\u1eaft \u0111\u1ea7u giao d\u1ecbch trong ng\u00e0y, r\u1ea5t quan tr\u1ecdng \u0111\u1ec3 n\u1eafm b\u1eaft c\u01a1 h\u1ed9i k\u1ecbp th\u1eddi quanh k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng ho\u1eb7c quy\u1ebft \u0111\u1ecbnh FDA.<\/li> <li><strong>Nhi\u1ec1u Ph\u01b0\u01a1ng Th\u1ee9c R\u00fat Ti\u1ec1n<\/strong><br>H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n cung c\u1ea5p s\u1ef1 linh ho\u1ea1t \u0111\u1ec3 nhanh ch\u00f3ng thu l\u1ee3i khi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tr\u1ea3i qua c\u00e1c giai \u0111o\u1ea1n t\u0103ng gi\u00e1 nhanh \u0111\u1eb7c tr\u01b0ng.<\/li> <\/ul> <p>C\u1ea5u tr\u00fac n\u1ec1n t\u1ea3ng \u0111\u1eb7c bi\u1ec7t c\u00f3 l\u1ee3i cho nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n x\u00e2y d\u1ef1ng v\u1ecb th\u1ebf trong c\u00e1c c\u1ed5 phi\u1ebfu h\u1ee9a h\u1eb9n nh\u01b0ng bi\u1ebfn \u0111\u1ed9ng th\u00f4ng qua t\u00edch l\u0169y d\u1ea7n thay v\u00ec \u0111\u1ea7u t\u01b0 m\u1ed9t l\u1ea7n l\u1edbn.<\/p> <h2>CRISPR Therapeutics: Ch\u1ec9nh S\u1eeda T\u01b0\u01a1ng Lai Y H\u1ecdc<\/h2> <p>CRISPR Therapeutics ho\u1ea1t \u0111\u1ed9ng t\u1ea1i giao \u0111i\u1ec3m c\u1ee7a c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u00e0 k\u1ef9 thu\u1eadt di truy\u1ec1n, ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p chuy\u1ec3n \u0111\u1ed5i s\u1eed d\u1ee5ng c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen CRISPR\/Cas9. S\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c c\u1ee7a c\u00f4ng ty, CASGEVY, l\u00e0 li\u1ec7u ph\u00e1p d\u1ef1a tr\u00ean CRISPR \u0111\u1ea7u ti\u00ean \u0111\u01b0\u1ee3c FDA ph\u00ea duy\u1ec7t cho b\u1ec7nh h\u1ed3ng c\u1ea7u h\u00ecnh li\u1ec1m v\u00e0 beta thalassemia.<\/p> <p><strong>V\u1ecb Tr\u00ed Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i<\/strong><\/p> <ul> <li>V\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng: 5,43 t\u1ef7 USD<\/li> <li>Trung t\u00e2m \u0111i\u1ec1u tr\u1ecb: 75 trung t\u00e2m \u0111\u00e3 k\u00edch ho\u1ea1t tr\u00ean to\u00e0n c\u1ea7u<\/li> <li>Ph\u1ea1m vi \u0111\u1ecba l\u00fd: \u0110\u01b0\u1ee3c ph\u00ea duy\u1ec7t t\u1ea1i M\u1ef9, EU, Anh, Canada v\u00e0 Trung \u0110\u00f4ng<\/li> <li>Pipeline: H\u01a1n 10 ch\u01b0\u01a1ng tr\u00ecnh l\u00e2m s\u00e0ng tr\u00ean nhi\u1ec1u l\u0129nh v\u1ef1c b\u1ec7nh kh\u00e1c nhau<\/li> <\/ul> <p>N\u1ec1n t\u1ea3ng c\u00f4ng ngh\u1ec7 c\u1ee7a c\u00f4ng ty cho ph\u00e9p c\u00e1c ch\u1ec9nh s\u1eeda gen ch\u00ednh x\u00e1c c\u00f3 th\u1ec3 \u0111i\u1ec1u tr\u1ecb h\u00e0ng tr\u0103m r\u1ed1i lo\u1ea1n di truy\u1ec1n, \u0111\u1ecbnh v\u1ecb CRSP nh\u01b0 m\u1ed9t nh\u00e2n t\u1ed1 n\u1ec1n t\u1ea3ng trong cu\u1ed9c c\u00e1ch m\u1ea1ng y h\u1ecdc di truy\u1ec1n \u0111ang n\u1ed5i l\u00ean.<\/p> <p><strong>S\u1ef1 Th\u1eadt Th\u00fa V\u1ecb N\u0103m 2025<\/strong>: CRISPR Therapeutics \u0111\u00e3 t\u1ea1o n\u00ean l\u1ecbch s\u1eed n\u0103m nay khi thang m\u00e1y t\u1ea1i tr\u1ee5 s\u1edf ch\u00ednh \u0111\u01b0\u1ee3c l\u1eadp tr\u00ecnh di truy\u1ec1n \u0111\u1ec3 ph\u00e1t ra c\u00e1c m\u00f9i h\u01b0\u01a1ng tr\u1ecb li\u1ec7u kh\u00e1c nhau \u1edf m\u1ed7i t\u1ea7ng \u2013 t\u1ea7ng tr\u1ec7t ph\u00e1t ra m\u00f9i o\u1ea3i h\u01b0\u01a1ng d\u1ecbu nh\u1eb9 gi\u00fap kh\u00e1ch tham quan b\u1edbt lo l\u1eafng, trong khi t\u1ea7ng R&amp;D ph\u00e1t ra h\u01b0\u01a1ng b\u1ea1c h\u00e0 gi\u00fap t\u0103ng s\u1ef1 t\u1ec9nh t\u00e1o cho c\u00e1c nh\u00e0 nghi\u00ean c\u1ee9u l\u00e0m vi\u1ec7c mu\u1ed9n v\u1edbi c\u00e1c li\u1ec7u ph\u00e1p \u0111\u1ed9t ph\u00e1!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>M\u1edf Kh\u00f3a T\u01b0\u01a1ng Lai Y H\u1ecdc Qua \u0110\u1ea7u T\u01b0 C\u1ed5 Phi\u1ebfu<\/h2>\n<p>Ch\u1ec9nh s\u1eeda gen \u0111\u1ea1i di\u1ec7n cho m\u1ed9t trong nh\u1eefng \u0111\u1ed9t ph\u00e1 y h\u1ecdc c\u00e1ch m\u1ea1ng nh\u1ea5t c\u1ee7a th\u1ebf h\u1ec7 ch\u00fang ta, v\u00e0 CRISPR Therapeutics \u0111\u1ee9ng \u1edf tuy\u1ebfn \u0111\u1ea7u c\u1ee7a s\u1ef1 chuy\u1ec3n \u0111\u1ed5i n\u00e0y. \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRSP c\u00f3 ngh\u0129a l\u00e0 b\u1ea1n \u0111ang mua v\u00e0o c\u00f4ng ngh\u1ec7 c\u00f3 th\u1ec3 \u0111\u1ecbnh ngh\u0129a l\u1ea1i c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh di truy\u1ec1n m\u00e3i m\u00e3i. C\u00f4ng ty ti\u00ean phong trong c\u00f4ng ngh\u1ec7 CRISPR\/Cas9 mang l\u1ea1i ti\u1ec1m n\u0103ng ch\u01b0a t\u1eebng c\u00f3 cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi \u0111\u1ed5i m\u1edbi c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ti\u00ean ti\u1ebfn.<\/p>\n<p><strong>\u1ea2nh Ch\u1ee5p Gi\u00e1 C\u1ed5 Phi\u1ebfu Hi\u1ec7n T\u1ea1i<\/strong><\/p>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 19 th\u00e1ng 8 n\u0103m 2025, CRISPR Therapeutics AG (CRSP) giao d\u1ecbch \u1edf m\u1ee9c <strong>57,59 USD<\/strong> m\u1ed7i c\u1ed5 phi\u1ebfu. C\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n s\u1ef1 bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong su\u1ed1t n\u0103m 2025, ph\u1ea3n \u00e1nh c\u1ea3 ti\u1ec1m n\u0103ng to l\u1edbn v\u00e0 r\u1ee7i ro \u0111\u00e1ng k\u1ec3 v\u1ed1n c\u00f3 trong \u0111\u1ea7u t\u01b0 ch\u1ec9nh s\u1eeda gen. V\u1edbi ph\u1ea1m vi 52 tu\u1ea7n t\u1eeb 30,04 USD \u0111\u1ebfn 71,13 USD, CRSP cung c\u1ea5p ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 \u0111\u00e1ng k\u1ec3 c\u00f9ng v\u1edbi r\u1ee7i ro gi\u1ea3m gi\u00e1 kh\u00f4ng nh\u1ecf.<\/p>\n<p><strong>C\u1ea3nh B\u00e1o Ng\u00e0y Quan Tr\u1ecdng: 4 Th\u00e1ng 11, 2025<\/strong><\/p>\n<p>H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y 4 th\u00e1ng 11 n\u0103m 2025 \u2013 \u0111\u00e2y l\u00e0 ng\u00e0y CRISPR Therapeutics s\u1ebd c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3 n\u0103m 2025. C\u00e1c m\u1eabu h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o thu nh\u1eadp n\u00e0y th\u01b0\u1eddng k\u00edch ho\u1ea1t c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3. B\u00e1o c\u00e1o qu\u00fd 2 g\u1ea7n \u0111\u00e2y c\u1ee7a c\u00f4ng ty v\u00e0o ng\u00e0y 4 th\u00e1ng 8 n\u0103m 2025 cung c\u1ea5p c\u00e1i nh\u00ecn s\u00e2u s\u1eafc v\u1ec1 nh\u1eefng g\u00ec c\u00f3 th\u1ec3 mong \u0111\u1ee3i.<\/p>\n<p>Trong b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 2 n\u0103m 2025, CRISPR \u0111\u00e3 v\u01b0\u1ee3t qua \u01b0\u1edbc t\u00ednh EPS (-1,29 USD so v\u1edbi -1,47 USD d\u1ef1 ki\u1ebfn) nh\u01b0ng l\u1ea1i b\u1ecf l\u1ee1 d\u1ef1 b\u00e1o doanh thu \u0111\u00e1ng k\u1ec3 (0,89 tri\u1ec7u USD so v\u1edbi 6,44 tri\u1ec7u USD d\u1ef1 ki\u1ebfn). M\u00f4 h\u00ecnh hi\u1ec7u su\u1ea5t h\u1ed7n h\u1ee3p n\u00e0y \u0111\u00e3 \u0111\u01b0\u1ee3c duy tr\u00ec:<\/p>\n<ul>\n<li><strong>Th\u00e1ng 2 n\u0103m 2025<\/strong>: V\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh EPS v\u1edbi b\u1ea5t ng\u1edd doanh thu m\u1ea1nh<\/li>\n<li><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: B\u1ecf l\u1ee1 c\u1ea3 m\u1ee5c ti\u00eau EPS v\u00e0 doanh thu<\/li>\n<li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: V\u01b0\u1ee3t EPS nh\u01b0ng b\u1ecf l\u1ee1 doanh thu m\u1ed9t c\u00e1ch \u0111\u00e1ng k\u1ec3<\/li>\n<\/ul>\n<p>B\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11 s\u1ebd \u0111\u1eb7c bi\u1ec7t quan tr\u1ecdng khi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 theo d\u00f5i c\u1eadp nh\u1eadt v\u1ec1 ti\u1ebfn tr\u00ecnh th\u01b0\u01a1ng m\u1ea1i h\u00f3a CASGEVY v\u00e0 c\u00e1c ph\u00e1t tri\u1ec3n th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng cho c\u00e1c ch\u01b0\u01a1ng tr\u00ecnh CTX310 v\u00e0 CTX112.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng: T\u00e0u L\u01b0\u1ee3n C\u1ea3m X\u00fac C\u1ee7a \u0110\u1ed5i M\u1edbi<\/h2>\n<p>CRISPR Therapeutics \u0111\u00e3 \u0111\u01b0a c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t chuy\u1ebfn \u0111i hoang d\u00e3 trong t\u00e1m th\u00e1ng \u0111\u1ea7u n\u0103m 2025, mang l\u1ea1i l\u1ee3i nhu\u1eadn <strong>51,75% t\u1eeb \u0111\u1ea7u n\u0103m \u0111\u1ebfn nay<\/strong> m\u1eb7c d\u00f9 c\u00f3 s\u1ef1 bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3.<\/p>\n<p><strong>D\u00f2ng Th\u1eddi Gian Bi\u1ebfn \u0110\u1ed9ng Gi\u00e1:<\/strong><\/p>\n<ul>\n<li><strong>Th\u00e1ng 1 n\u0103m 2025<\/strong>: Giao d\u1ecbch quanh m\u1ee9c 40-45 USD sau \u0111\u1ee3t gi\u1ea3m n\u0103m 2024<\/li>\n<li><strong>Th\u00e1ng 3 n\u0103m 2025<\/strong>: T\u0103ng d\u1ea7n l\u00ean 48-52 USD nh\u1edd l\u1ea1c quan v\u1ec1 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/li>\n<li><strong>Th\u00e1ng 5 n\u0103m 2025<\/strong>: T\u0103ng v\u1ecdt l\u00ean 58-62 USD nh\u1edd tin t\u1ee9c v\u1ec1 c\u1ed9t m\u1ed1c quy \u0111\u1ecbnh<\/li>\n<li><strong>Th\u00e1ng 7 n\u0103m 2025<\/strong>: \u0110\u1ec9nh \u0111i\u1ec3m \u1edf 64,76 USD v\u1edbi th\u00f4ng b\u00e1o m\u1edf r\u1ed9ng CASGEVY<\/li>\n<li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: T\u00edch l\u0169y quanh 57-60 USD v\u1edbi ho\u1ea1t \u0111\u1ed9ng ch\u1ed1t l\u1eddi<\/li>\n<\/ul>\n<p>Hi\u1ec7u su\u1ea5t c\u1ee7a c\u1ed5 phi\u1ebfu th\u1ec3 hi\u1ec7n \u0111\u1eb7c \u0111i\u1ec3m \u0111i\u1ec3n h\u00ecnh c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u2013 t\u0103ng m\u1ea1nh khi c\u00f3 tin t\u00edch c\u1ef1c v\u00e0 sau \u0111\u00f3 l\u00e0 giai \u0111o\u1ea1n t\u00edch l\u0169y. M\u1ee9c <strong>t\u0103ng 35-40% t\u1eeb th\u00e1ng 6 \u0111\u1ebfn th\u00e1ng 7<\/strong> cho th\u1ea5y t\u00e2m l\u00fd c\u00f3 th\u1ec3 thay \u0111\u1ed5i nhanh ch\u00f3ng trong l\u0129nh v\u1ef1c n\u00e0y d\u1ef1a tr\u00ean c\u1eadp nh\u1eadt l\u00e2m s\u00e0ng v\u00e0 ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh.<\/p>\n<h2>D\u1ef1 B\u00e1o Gi\u00e1: \u0110\u1ecbnh H\u01b0\u1edbng Bi\u00ean Gi\u1edbi \u0110\u1ea7u T\u01b0 Di Truy\u1ec1n<\/h2>\n<ul>\n<li><strong>M\u1ee5c Ti\u00eau Cu\u1ed1i N\u0103m 2025: 86-91 USD<\/strong><br \/>C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n CRSP c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 86,42 \u0111\u1ebfn 91,28 USD v\u00e0o th\u00e1ng 12 n\u0103m 2025, t\u01b0\u01a1ng \u0111\u01b0\u01a1ng m\u1ee9c t\u0103ng ti\u1ec1m n\u0103ng 50-58% so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i. S\u1ef1 l\u1ea1c quan n\u00e0y xu\u1ea5t ph\u00e1t t\u1eeb k\u1ef3 v\u1ecdng t\u0103ng t\u1ed1c doanh thu CASGEVY v\u00e0 c\u00e1c k\u1ebft qu\u1ea3 d\u1eef li\u1ec7u l\u00e2m s\u00e0ng t\u00edch c\u1ef1c.<\/li>\n<li><strong>Tri\u1ec3n V\u1ecdng 2026: 83-85 USD<\/strong><br \/>T\u0103ng tr\u01b0\u1edfng v\u1eeba ph\u1ea3i h\u01a1n khi c\u00f4ng ty chuy\u1ec3n t\u1eeb giai \u0111o\u1ea1n nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n thu\u1ea7n t\u00fay sang giai \u0111o\u1ea1n th\u1ef1c thi th\u01b0\u01a1ng m\u1ea1i.<\/li>\n<li><strong>D\u1ef1 B\u00e1o 2028: 100-120 USD<\/strong><br \/>Gi\u1ea3 \u0111\u1ecbnh ph\u00e1t tri\u1ec3n th\u00e0nh c\u00f4ng pipeline v\u00e0 ph\u00ea duy\u1ec7t th\u00eam li\u1ec7u ph\u00e1p.<\/li>\n<li><strong>T\u1ea7m Nh\u00ecn 2030: 140-160 USD<\/strong><br \/>Ti\u1ec1m n\u0103ng d\u00e0i h\u1ea1n n\u1ebfu ch\u1ec9nh s\u1eeda gen tr\u1edf th\u00e0nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb y h\u1ecdc ph\u1ed5 bi\u1ebfn.<\/li>\n<li><strong>K\u1ebft Lu\u1eadn: MUA<\/strong> d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 ch\u1ecbu r\u1ee7i ro v\u1edbi t\u1ea7m nh\u00ecn d\u00e0i h\u1ea1n. Ti\u1ec1m n\u0103ng n\u1ec1n t\u1ea3ng c\u00f4ng ngh\u1ec7 c\u1ee7a c\u00f4ng ty v\u01b0\u1ee3t tr\u1ed9i so v\u1edbi c\u00e1c th\u00e1ch th\u1ee9c t\u00e0i ch\u00ednh ng\u1eafn h\u1ea1n.<\/li>\n<\/ul>\n<h2>\u0110\u00e1nh Gi\u00e1 R\u1ee7i Ro: \u0110i\u1ec1u H\u01b0\u1edbng M\u1ecf M\u00ecn C\u00f4ng Ngh\u1ec7 Sinh H\u1ecdc<\/h2>\n<ul>\n<li><strong>Nguy C\u01a1 Bi\u1ebfn \u0110\u1ed9ng Cao<\/strong><br \/>CRSP th\u1ec3 hi\u1ec7n dao \u0111\u1ed9ng gi\u00e1 c\u1ef1c \u0111oan v\u1edbi \u0111\u1ed9 bi\u1ebfn \u0111\u1ed9ng l\u1ecbch s\u1eed 30 ng\u00e0y l\u00e0 0,4585. C\u00e1c bi\u1ebfn \u0111\u1ed9ng h\u00e0ng ng\u00e0y t\u1eeb 4-8% l\u00e0 ph\u1ed5 bi\u1ebfn, khi\u1ebfn vi\u1ec7c x\u00e1c \u0111\u1ecbnh k\u00edch th\u01b0\u1edbc v\u1ecb th\u1ebf tr\u1edf n\u00ean quan tr\u1ecdng.<\/li>\n<li><strong>Lo Ng\u1ea1i V\u1ec1 T\u00ednh B\u1ec1n V\u1eefng T\u00e0i Ch\u00ednh<\/strong><br \/>C\u00f4ng ty ti\u00eau t\u1ed1n kho\u1ea3ng 200 tri\u1ec7u USD m\u1ed7i qu\u00fd trong khi doanh thu r\u1ea5t th\u1ea5p. T\u1ed1c \u0111\u1ed9 \u0111\u1ed1t ti\u1ec1n n\u00e0y \u0111\u00f2i h\u1ecfi huy \u0111\u1ed9ng v\u1ed1n trong t\u01b0\u01a1ng lai c\u00f3 th\u1ec3 l\u00e0m pha lo\u00e3ng c\u1ed5 \u0111\u00f4ng.<\/li>\n<li><strong>B\u1ea5t \u1ed4n Quy \u0110\u1ecbnh<\/strong><br \/>Ch\u1ec9nh s\u1eeda gen \u0111\u1ed1i m\u1eb7t v\u1edbi c\u00e1c khung ph\u00e1p l\u00fd \u0111ang ph\u00e1t tri\u1ec3n tr\u00ean to\u00e0n c\u1ea7u. B\u1ea5t k\u1ef3 quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c n\u00e0o v\u1ec1 quy \u0111\u1ecbnh c\u00f3 th\u1ec3 l\u00e0m gi\u00e1 c\u1ed5 phi\u1ebfu s\u1ee5p \u0111\u1ed5 qua \u0111\u00eam.<\/li>\n<li><strong>K\u1ebft Qu\u1ea3 Nh\u1ecb Ph\u00e2n Th\u1eed Nghi\u1ec7m L\u00e2m S\u00e0ng<\/strong><br \/>Th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m th\u01b0\u1eddng g\u00e2y gi\u1ea3m gi\u00e1 tr\u00ean 50%, trong khi th\u00e0nh c\u00f4ng c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t t\u0103ng gi\u00e1 tr\u00ean 100%.<\/li>\n<\/ul>\n<h2>T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c: Cu\u1ed9c C\u00e1ch M\u1ea1ng Di Truy\u1ec1n T\u0103ng T\u1ed1c<\/h2>\n<ul>\n<li><strong>M\u1edf R\u1ed9ng Th\u01b0\u01a1ng M\u1ea1i CASGEVY<\/strong><br \/>K\u00edch ho\u1ea1t 75 trung t\u00e2m \u0111i\u1ec1u tr\u1ecb \u0111\u01b0\u1ee3c \u1ee7y quy\u1ec1n tr\u00ean to\u00e0n c\u1ea7u \u0111\u1ea1i di\u1ec7n cho s\u1ef1 x\u00e2y d\u1ef1ng c\u01a1 s\u1edf h\u1ea1 t\u1ea7ng l\u1edbn, d\u1ef1 ki\u1ebfn th\u00fac \u0111\u1ea9y t\u0103ng tr\u01b0\u1edfng doanh thu trong giai \u0111o\u1ea1n 2025-2026.<\/li>\n<li><strong>T\u0103ng T\u1ed1c Ti\u1ebfn \u0110\u1ed9 Pipeline<\/strong><br \/>CTX310 \u0111\u01b0\u1ee3c FDA c\u00f4ng nh\u1eadn l\u00e0 li\u1ec7u ph\u00e1p ti\u00ean ti\u1ebfn trong y h\u1ecdc t\u00e1i t\u1ea1o v\u00e0 CTX112 m\u1edf r\u1ed9ng sang c\u00e1c b\u1ec7nh t\u1ef1 mi\u1ec5n t\u1ea1o ra nhi\u1ec1u ch\u1ea5t x\u00fac t\u00e1c gi\u00e1 tr\u1ecb.<\/li>\n<li><strong>\u0110\u1ed9ng L\u1ef1c Ng\u00e0nh<\/strong><br \/>Th\u1ecb tr\u01b0\u1eddng ch\u1ec9nh s\u1eeda gen d\u1ef1 ki\u1ebfn t\u0103ng tr\u01b0\u1edfng v\u1edbi t\u1ed1c \u0111\u1ed9 CAGR 22% \u0111\u1ebfn n\u0103m 2030, t\u1ea1o ra l\u00e0n s\u00f3ng thu\u1eadn l\u1ee3i cho t\u1ea5t c\u1ea3 c\u00e1c b\u00ean tham gia.<\/li>\n<li><strong>\u0110\u1ed1i T\u00e1c Chi\u1ebfn L\u01b0\u1ee3c<\/strong><br \/>H\u1ee3p t\u00e1c g\u1ea7n \u0111\u00e2y v\u1edbi Sirius Therapeutics ph\u00e1t tri\u1ec3n siRNA cho th\u1ea5y \u0111\u1ed9ng l\u1ef1c ph\u00e1t tri\u1ec3n kinh doanh.<\/li>\n<\/ul>\n<h2>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Tin T\u1ee9c G\u1ea7n \u0110\u00e2y<\/h2>\n<ul>\n<li><strong>B\u00e1o C\u00e1o Thu Nh\u1eadp Ng\u00e0y 4 Th\u00e1ng 8, 2025<\/strong>: Ph\u1ea3n \u1ee9ng h\u1ed7n h\u1ee3p v\u1edbi vi\u1ec7c v\u01b0\u1ee3t EPS nh\u01b0ng b\u1ecf l\u1ee1 doanh thu g\u00e2y nh\u1ea7m l\u1eabn ban \u0111\u1ea7u r\u1ed3i \u1ed5n \u0111\u1ecbnh.<\/li>\n<li><strong>Tri\u1ec3n Khai To\u00e0n C\u1ea7u CASGEVY<\/strong>: M\u1edf r\u1ed9ng trung t\u00e2m \u0111i\u1ec1u tr\u1ecb l\u00ean 75 \u0111\u1ecba \u0111i\u1ec3m t\u1ea1o \u0111\u1ed9ng l\u1ef1c t\u00edch c\u1ef1c b\u1ec1n v\u1eefng \u0111\u1ebfn th\u00e1ng 7.<\/li>\n<li><strong>M\u1edf R\u1ed9ng CTX112 Sang B\u1ec7nh T\u1ef1 Mi\u1ec5n<\/strong>: Th\u00f4ng b\u00e1o th\u00e1ng 7 k\u00edch ho\u1ea1t t\u0103ng gi\u00e1 16% trong m\u1ed9t ng\u00e0y khi nh\u00e0 \u0111\u1ea7u t\u01b0 nh\u1eadn ra l\u1ee3i \u00edch \u0111a d\u1ea1ng h\u00f3a pipeline.<\/li>\n<li><strong>\u0110\u01b0\u1ee3c TIME Vinh Danh<\/strong>: \u0110\u01b0\u1ee3c li\u1ec7t k\u00ea trong danh s\u00e1ch C\u00e1c C\u00f4ng Ty \u1ea2nh H\u01b0\u1edfng Nh\u1ea5t c\u1ee7a TIME mang l\u1ea1i uy t\u00edn v\u00e0 thu h\u00fat s\u1ef1 ch\u00fa \u00fd c\u1ee7a nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n.<\/li>\n<\/ul>\n<h2>K\u1ebft Lu\u1eadn Chi\u1ebfn L\u01b0\u1ee3c \u0110\u1ea7u T\u01b0<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u00e0 giao d\u1ecbch m\u1edbi b\u1eaft \u0111\u1ea7u h\u00f4m nay:<\/p>\n<ol>\n<li><strong>B\u1eaft \u0110\u1ea7u Nh\u1ecf<\/strong> \u2013 Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 2-3% danh m\u1ee5c cho CRSP do bi\u1ebfn \u0111\u1ed9ng c\u1ef1c \u0111oan<\/li>\n<li><strong>Trung B\u00ecnh Gi\u00e1 \u0110\u00f4 La<\/strong> \u2013 X\u00e2y d\u1ef1ng v\u1ecb th\u1ebf d\u1ea7n d\u1ea7n trong 3-6 th\u00e1ng thay v\u00ec \u0111\u1ea7u t\u01b0 m\u1ed9t l\u1ea7n l\u1edbn<\/li>\n<li><strong>\u0110\u1eb7t M\u1ee9c C\u1eaft L\u1ed7<\/strong> \u2013 B\u1ea3o v\u1ec7 kh\u1ecfi s\u1ee5t gi\u1ea3m th\u1ea3m kh\u1ed1c v\u1edbi m\u1ee9c c\u1eaft l\u1ed7 25-30%<\/li>\n<li><strong>Theo D\u00f5i B\u00e1o C\u00e1o Thu Nh\u1eadp Th\u00e1ng 11<\/strong> \u2013 Chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng l\u1edbn sau b\u00e1o c\u00e1o thu nh\u1eadp<\/li>\n<\/ol>\n<p>Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc c\u1ee7a nh\u00e0 giao d\u1ecbch: &#8220;Giao d\u1ecbch CRSP gi\u1ed1ng nh\u01b0 ch\u1ec9nh s\u1eeda gen \u2013 \u0111\u00f4i khi b\u1ea1n gh\u00e9p n\u1ed1i \u0111\u01b0\u1ee3c kho\u1ea3n \u0111\u1ea7u t\u01b0 ho\u00e0n h\u1ea3o, \u0111\u00f4i khi b\u1ea1n t\u1ea1o ra v\u1ecb th\u1ebf \u0111\u1ed9t bi\u1ebfn \u0103n m\u00f2n danh m\u1ee5c \u0111\u1ea7u t\u01b0 c\u1ee7a b\u1ea1n!&#8221;<\/p>\n<h2>C\u00e1ch Mua C\u1ed5 Phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; Th\u1ef1c Thi \u0110\u1ea7u T\u01b0<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea7m Quan Tr\u1ecdng Chi\u1ebfn L\u01b0\u1ee3c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Nghi\u00ean C\u1ee9u C\u00e1c L\u1ef1a Ch\u1ecdn M\u00f4i Gi\u1edbi<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p truy c\u1eadp NASDAQ v\u00e0 c\u1ea5u tr\u00fac hoa h\u1ed3ng h\u1ee3p l\u00fd<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>N\u1ea1p Ti\u1ec1n V\u00e0o T\u00e0i Kho\u1ea3n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf \u0111\u1ec3 th\u1eed chi\u1ebfn l\u01b0\u1ee3c tr\u01b0\u1edbc khi cam k\u1ebft l\u1edbn h\u01a1n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>L\u1ef1a Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td>\n<td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o trong \u0111i\u1ec1u ki\u1ec7n bi\u1ebfn \u0111\u1ed9ng<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>\u0110\u1ecbnh C\u1ee1 V\u1ecb Th\u1ebf<\/td>\n<td>Gi\u1eef v\u1ecb th\u1ebf ban \u0111\u1ea7u d\u01b0\u1edbi 3% t\u1ed5ng gi\u00e1 tr\u1ecb danh m\u1ee5c<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Thi\u1ebft L\u1eadp Gi\u00e1m S\u00e1t<\/td>\n<td>Thi\u1ebft l\u1eadp c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c ng\u00e0y b\u00e1o c\u00e1o thu nh\u1eadp v\u00e0 c\u00e1c m\u1ee9c k\u1ef9 thu\u1eadt<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Qu\u00e1 tr\u00ecnh n\u00e0y \u0111\u00f2i h\u1ecfi hi\u1ec3u r\u1eb1ng \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc kh\u00e1c bi\u1ec7t c\u0103n b\u1ea3n so v\u1edbi ch\u1ecdn c\u1ed5 phi\u1ebfu truy\u1ec1n th\u1ed1ng. B\u1ea1n \u0111ang \u0111\u1eb7t c\u01b0\u1ee3c v\u00e0o th\u00e0nh c\u00f4ng khoa h\u1ecdc thay v\u00ec ch\u1ec9 l\u00e0 v\u01b0\u1ee3t k\u1ef3 v\u1ecdng thu nh\u1eadp qu\u00fd.<\/p>\n<h2>L\u1ee3i Th\u1ebf Pocket Option: C\u1eeda Ng\u00f5 \u0110\u1ebfn S\u1ef1 Gi\u00e0u C\u00f3 Di Truy\u1ec1n<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm l\u1ed1i v\u00e0o d\u1ec5 d\u00e0ng v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu ti\u1ec1m n\u0103ng cao nh\u01b0 CRSP, Pocket Option cung c\u1ea5p c\u00e1c l\u1ee3i th\u1ebf ri\u00eang bi\u1ec7t ph\u00f9 h\u1ee3p ho\u00e0n h\u1ea3o v\u1edbi chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc:<\/p>\n<ul>\n<li><strong>Y\u00eau C\u1ea7u N\u1ea1p Ti\u1ec1n T\u1ed1i Thi\u1ec3u Linh Ho\u1ea1t<\/strong><br \/>Ch\u1ec9 v\u1edbi y\u00eau c\u1ea7u n\u1ea1p t\u1ed1i thi\u1ec3u 5 USD, nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 th\u1eed nghi\u1ec7m v\u1edbi CRSP m\u00e0 kh\u00f4ng c\u1ea7n cam k\u1ebft v\u1ed1n l\u1edbn. \u0110i\u1ec1u n\u00e0y cho ph\u00e9p th\u1eed nghi\u1ec7m ki\u1ec3m so\u00e1t r\u1ee7i ro v\u1edbi c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng.<\/li>\n<li><strong>K\u00edch Ho\u1ea1t T\u00e0i Kho\u1ea3n Nhanh<\/strong><br \/>Quy tr\u00ecnh KYC m\u1ed9t t\u00e0i li\u1ec7u cho ph\u00e9p b\u1eaft \u0111\u1ea7u giao d\u1ecbch trong ng\u00e0y, r\u1ea5t quan tr\u1ecdng \u0111\u1ec3 n\u1eafm b\u1eaft c\u01a1 h\u1ed9i k\u1ecbp th\u1eddi quanh k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng ho\u1eb7c quy\u1ebft \u0111\u1ecbnh FDA.<\/li>\n<li><strong>Nhi\u1ec1u Ph\u01b0\u01a1ng Th\u1ee9c R\u00fat Ti\u1ec1n<\/strong><br \/>H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n cung c\u1ea5p s\u1ef1 linh ho\u1ea1t \u0111\u1ec3 nhanh ch\u00f3ng thu l\u1ee3i khi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tr\u1ea3i qua c\u00e1c giai \u0111o\u1ea1n t\u0103ng gi\u00e1 nhanh \u0111\u1eb7c tr\u01b0ng.<\/li>\n<\/ul>\n<p>C\u1ea5u tr\u00fac n\u1ec1n t\u1ea3ng \u0111\u1eb7c bi\u1ec7t c\u00f3 l\u1ee3i cho nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n x\u00e2y d\u1ef1ng v\u1ecb th\u1ebf trong c\u00e1c c\u1ed5 phi\u1ebfu h\u1ee9a h\u1eb9n nh\u01b0ng bi\u1ebfn \u0111\u1ed9ng th\u00f4ng qua t\u00edch l\u0169y d\u1ea7n thay v\u00ec \u0111\u1ea7u t\u01b0 m\u1ed9t l\u1ea7n l\u1edbn.<\/p>\n<h2>CRISPR Therapeutics: Ch\u1ec9nh S\u1eeda T\u01b0\u01a1ng Lai Y H\u1ecdc<\/h2>\n<p>CRISPR Therapeutics ho\u1ea1t \u0111\u1ed9ng t\u1ea1i giao \u0111i\u1ec3m c\u1ee7a c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u00e0 k\u1ef9 thu\u1eadt di truy\u1ec1n, ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p chuy\u1ec3n \u0111\u1ed5i s\u1eed d\u1ee5ng c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen CRISPR\/Cas9. S\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c c\u1ee7a c\u00f4ng ty, CASGEVY, l\u00e0 li\u1ec7u ph\u00e1p d\u1ef1a tr\u00ean CRISPR \u0111\u1ea7u ti\u00ean \u0111\u01b0\u1ee3c FDA ph\u00ea duy\u1ec7t cho b\u1ec7nh h\u1ed3ng c\u1ea7u h\u00ecnh li\u1ec1m v\u00e0 beta thalassemia.<\/p>\n<p><strong>V\u1ecb Tr\u00ed Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i<\/strong><\/p>\n<ul>\n<li>V\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng: 5,43 t\u1ef7 USD<\/li>\n<li>Trung t\u00e2m \u0111i\u1ec1u tr\u1ecb: 75 trung t\u00e2m \u0111\u00e3 k\u00edch ho\u1ea1t tr\u00ean to\u00e0n c\u1ea7u<\/li>\n<li>Ph\u1ea1m vi \u0111\u1ecba l\u00fd: \u0110\u01b0\u1ee3c ph\u00ea duy\u1ec7t t\u1ea1i M\u1ef9, EU, Anh, Canada v\u00e0 Trung \u0110\u00f4ng<\/li>\n<li>Pipeline: H\u01a1n 10 ch\u01b0\u01a1ng tr\u00ecnh l\u00e2m s\u00e0ng tr\u00ean nhi\u1ec1u l\u0129nh v\u1ef1c b\u1ec7nh kh\u00e1c nhau<\/li>\n<\/ul>\n<p>N\u1ec1n t\u1ea3ng c\u00f4ng ngh\u1ec7 c\u1ee7a c\u00f4ng ty cho ph\u00e9p c\u00e1c ch\u1ec9nh s\u1eeda gen ch\u00ednh x\u00e1c c\u00f3 th\u1ec3 \u0111i\u1ec1u tr\u1ecb h\u00e0ng tr\u0103m r\u1ed1i lo\u1ea1n di truy\u1ec1n, \u0111\u1ecbnh v\u1ecb CRSP nh\u01b0 m\u1ed9t nh\u00e2n t\u1ed1 n\u1ec1n t\u1ea3ng trong cu\u1ed9c c\u00e1ch m\u1ea1ng y h\u1ecdc di truy\u1ec1n \u0111ang n\u1ed5i l\u00ean.<\/p>\n<p><strong>S\u1ef1 Th\u1eadt Th\u00fa V\u1ecb N\u0103m 2025<\/strong>: CRISPR Therapeutics \u0111\u00e3 t\u1ea1o n\u00ean l\u1ecbch s\u1eed n\u0103m nay khi thang m\u00e1y t\u1ea1i tr\u1ee5 s\u1edf ch\u00ednh \u0111\u01b0\u1ee3c l\u1eadp tr\u00ecnh di truy\u1ec1n \u0111\u1ec3 ph\u00e1t ra c\u00e1c m\u00f9i h\u01b0\u01a1ng tr\u1ecb li\u1ec7u kh\u00e1c nhau \u1edf m\u1ed7i t\u1ea7ng \u2013 t\u1ea7ng tr\u1ec7t ph\u00e1t ra m\u00f9i o\u1ea3i h\u01b0\u01a1ng d\u1ecbu nh\u1eb9 gi\u00fap kh\u00e1ch tham quan b\u1edbt lo l\u1eafng, trong khi t\u1ea7ng R&amp;D ph\u00e1t ra h\u01b0\u01a1ng b\u1ea1c h\u00e0 gi\u00fap t\u0103ng s\u1ef1 t\u1ec9nh t\u00e1o cho c\u00e1c nh\u00e0 nghi\u00ean c\u1ee9u l\u00e0m vi\u1ec7c mu\u1ed9n v\u1edbi c\u00e1c li\u1ec7u ph\u00e1p \u0111\u1ed9t ph\u00e1!<\/p>\n"},"faq":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu CRSP th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng m\u00f4i gi\u1edbi c\u00f3 truy c\u1eadp NASDAQ. N\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf, s\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0 theo d\u00f5i c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp quan tr\u1ecdng \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh \u0111\u1ea7u t\u01b0 h\u1ee3p l\u00fd."},{"question":"CRISPR Therapeutics AG c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o trong t\u01b0\u01a1ng lai?","answer":"C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu CRSP c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 86 \u0111\u1ebfn 91 USD v\u00e0o cu\u1ed1i n\u0103m 2025, v\u1edbi ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n l\u00ean \u0111\u1ebfn 140-160 USD v\u00e0o n\u0103m 2030 n\u1ebfu c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen tr\u1edf th\u00e0nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb y h\u1ecdc ph\u1ed5 bi\u1ebfn."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o CRISPR Therapeutics l\u00e0 g\u00ec?","answer":"R\u1ee7i ro bao g\u1ed3m bi\u1ebfn \u0111\u1ed9ng gi\u00e1 cao, lo ng\u1ea1i v\u1ec1 t\u00ednh b\u1ec1n v\u1eefng t\u00e0i ch\u00ednh do t\u1ed1c \u0111\u1ed9 \u0111\u1ed1t ti\u1ec1n l\u1edbn, b\u1ea5t \u1ed5n v\u1ec1 quy \u0111\u1ecbnh tr\u00ean to\u00e0n c\u1ea7u v\u00e0 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng c\u00f3 th\u1ec3 g\u00e2y bi\u1ebfn \u0111\u1ed9ng m\u1ea1nh v\u1ec1 gi\u00e1 c\u1ed5 phi\u1ebfu."},{"question":"CASGEVY l\u00e0 g\u00ec v\u00e0 vai tr\u00f2 c\u1ee7a n\u00f3 trong c\u00f4ng ty nh\u01b0 th\u1ebf n\u00e0o?","answer":"CASGEVY l\u00e0 li\u1ec7u ph\u00e1p d\u1ef1a tr\u00ean c\u00f4ng ngh\u1ec7 CRISPR \u0111\u1ea7u ti\u00ean \u0111\u01b0\u1ee3c FDA ph\u00ea duy\u1ec7t \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh h\u1ed3ng c\u1ea7u h\u00ecnh li\u1ec1m v\u00e0 beta thalassemia. \u0110\u00e2y l\u00e0 s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c c\u1ee7a CRISPR Therapeutics v\u00e0 \u0111\u00f3ng vai tr\u00f2 quan tr\u1ecdng trong t\u0103ng tr\u01b0\u1edfng doanh thu v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o CRSP?","answer":"Pocket Option cung c\u1ea5p y\u00eau c\u1ea7u n\u1ea1p ti\u1ec1n t\u1ed1i thi\u1ec3u th\u1ea5p, k\u00edch ho\u1ea1t t\u00e0i kho\u1ea3n nhanh ch\u00f3ng v\u00e0 nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n linh ho\u1ea1t, gi\u00fap nh\u00e0 \u0111\u1ea7u t\u01b0 d\u1ec5 d\u00e0ng ti\u1ebfp c\u1eadn v\u00e0 qu\u1ea3n l\u00fd \u0111\u1ea7u t\u01b0 v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng nh\u01b0 CRSP."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu CRSP th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng m\u00f4i gi\u1edbi c\u00f3 truy c\u1eadp NASDAQ. N\u00ean b\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n nh\u1ecf, s\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0 theo d\u00f5i c\u00e1c b\u00e1o c\u00e1o thu nh\u1eadp quan tr\u1ecdng \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh \u0111\u1ea7u t\u01b0 h\u1ee3p l\u00fd."},{"question":"CRISPR Therapeutics AG c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o trong t\u01b0\u01a1ng lai?","answer":"C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu CRSP c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 86 \u0111\u1ebfn 91 USD v\u00e0o cu\u1ed1i n\u0103m 2025, v\u1edbi ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n l\u00ean \u0111\u1ebfn 140-160 USD v\u00e0o n\u0103m 2030 n\u1ebfu c\u00f4ng ngh\u1ec7 ch\u1ec9nh s\u1eeda gen tr\u1edf th\u00e0nh ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb y h\u1ecdc ph\u1ed5 bi\u1ebfn."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o CRISPR Therapeutics l\u00e0 g\u00ec?","answer":"R\u1ee7i ro bao g\u1ed3m bi\u1ebfn \u0111\u1ed9ng gi\u00e1 cao, lo ng\u1ea1i v\u1ec1 t\u00ednh b\u1ec1n v\u1eefng t\u00e0i ch\u00ednh do t\u1ed1c \u0111\u1ed9 \u0111\u1ed1t ti\u1ec1n l\u1edbn, b\u1ea5t \u1ed5n v\u1ec1 quy \u0111\u1ecbnh tr\u00ean to\u00e0n c\u1ea7u v\u00e0 k\u1ebft qu\u1ea3 th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng c\u00f3 th\u1ec3 g\u00e2y bi\u1ebfn \u0111\u1ed9ng m\u1ea1nh v\u1ec1 gi\u00e1 c\u1ed5 phi\u1ebfu."},{"question":"CASGEVY l\u00e0 g\u00ec v\u00e0 vai tr\u00f2 c\u1ee7a n\u00f3 trong c\u00f4ng ty nh\u01b0 th\u1ebf n\u00e0o?","answer":"CASGEVY l\u00e0 li\u1ec7u ph\u00e1p d\u1ef1a tr\u00ean c\u00f4ng ngh\u1ec7 CRISPR \u0111\u1ea7u ti\u00ean \u0111\u01b0\u1ee3c FDA ph\u00ea duy\u1ec7t \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh h\u1ed3ng c\u1ea7u h\u00ecnh li\u1ec1m v\u00e0 beta thalassemia. \u0110\u00e2y l\u00e0 s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c c\u1ee7a CRISPR Therapeutics v\u00e0 \u0111\u00f3ng vai tr\u00f2 quan tr\u1ecdng trong t\u0103ng tr\u01b0\u1edfng doanh thu v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o CRSP?","answer":"Pocket Option cung c\u1ea5p y\u00eau c\u1ea7u n\u1ea1p ti\u1ec1n t\u1ed1i thi\u1ec3u th\u1ea5p, k\u00edch ho\u1ea1t t\u00e0i kho\u1ea3n nhanh ch\u00f3ng v\u00e0 nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n linh ho\u1ea1t, gi\u00fap nh\u00e0 \u0111\u1ea7u t\u01b0 d\u1ec5 d\u00e0ng ti\u1ebfp c\u1eadn v\u00e0 qu\u1ea3n l\u00fd \u0111\u1ea7u t\u01b0 v\u00e0o c\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng nh\u01b0 CRSP."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:36:34+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)\",\"datePublished\":\"2025-08-19T13:36:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-19T13:36:34+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:36:34+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","datePublished":"2025-08-19T13:36:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-19T13:36:34+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":338046,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Como comprar a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP) - Investimento em a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/338040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=338040"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/338040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=338040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=338040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=338040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}